SCHEMBL17459686

SCHEMBL17459686

CC(C)/C=C1/CCCN(C(=O)OC(C)(C)C)C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.35
NFKB1 P19838 4/20 0.33
NFKB2 Q00653 4/20 0.33
RELA Q04206 4/20 0.33
CYP11B2 P19099 2/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
CTSK P43235 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BUB1 O43683 1/20 0.32
HTT P42858 2/20 0.32
ATM Q13315 1/20 0.32
PREP P48147 1/20 0.32
HPGD P15428 1/20 0.31
PDK4 Q16654 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17459688 1.00 BRD4 (0.35) BRD4NFKB1NFKB2RELACYP11B2
SCHEMBL17459703 0.79 INMT (0.33) SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL17459701 0.79 INMT (0.33) SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4621580 0.79 USP2 (0.40) BRD4CTSKUSP2SMN1; SMN2BUB1
SCHEMBL17459694 0.76 SMN1; SMN2 (0.38) NFKB1NFKB2RELASMN1; SMN2HTT
SCHEMBL24569555 0.76 DDB1 (0.32) BUB1
SCHEMBL29887993 0.76 DDB1 (0.32) BUB1
SCHEMBL24569558 0.76 DDB1 (0.32) BUB1
SCHEMBL13617428 0.75 ESR2 (0.37) BRD4CYP11B2CTSKUSP2SMN1; SMN2
SCHEMBL21348242 0.74 USP2 (0.34) BRD4CTSKUSP2SMN1; SMN2PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10758524-B2 Compositions and methods for selectively depleting senescent cells BIOVENTURES, LLC (US) 2020-09-01 US disclosed
US-20180369223-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-12-27 US disclosed
US-10071087-B2 Compositions and methods for selectively depleting senescent cells BIOVENTURES, LLC (US) 2018-09-11 US disclosed
US-20170246155-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS BIOVENTURES, LLC 2017-08-31 US disclosed
EP-3177144-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS Bioventures, LLC. (US) 2017-06-14 EP disclosed
WO-2016014625-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10071087-B2 Compositions and methods for selectively depleting senescent cells CD47, MCL1, LIMS1 BRD4 1552/4885NFKB1 428/4885NFKB2 564/4885
US-10758524-B2 Compositions and methods for selectively depleting senescent cells CD47, MCL1, LIMS1 BRD4 1552/4885NFKB1 428/4885NFKB2 564/4885
US-20170246155-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS CD47, MCL1, LIMS1 BRD4 1552/4885NFKB1 428/4885NFKB2 564/4885
US-20180369223-A1 COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS CD47, MCL1, LIMS1 BRD4 1552/4885NFKB1 428/4885NFKB2 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.